Shuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug Study

Dow Jones09-05

By Josh Beckerman

Shuttle Pharmaceuticals Holdings filed delayed financial statements and reported progress in a clinical trial of cancer drug ropidoxuridine.

Shuttle filed its 10-Q for the second quarter along with amended filings for the first quarter and 2023. As a result, it regained compliance with Nasdaq Listing Rule 5250(c), the company said Wednesday.

The company's former auditor BF Borgers was banned from public-company work by the Securities and Exchange Commission in May for alleged fraud.

Shuttle said enrollment of patients in the Phase 2 clinical trial of ropidoxuridine for treatment of patients with glioblastoma has recently opened following the entry of agreements with two site locations to administer the trial.

During the regular trading session Wednesday, Shuttle shares rose 9% on volume of 10.8 million shares, compared with a 65-day average of 103,282. The stock was recently up 4% after hours, to $2.47.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 04, 2024 17:38 ET (21:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465998537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-05 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465998537","market":"hk","top_or_hot":-1,"title":"Shuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shuttle Pharmaceuticals Holdings filed delayed financial statements and reported progress in a clinical trial of cancer drug ropidoxuridine. \n</p>\n<p>\n  Shuttle filed its 10-Q for the second quarter along with amended filings for the first quarter and 2023. As a result, it regained compliance with Nasdaq Listing Rule 5250(c), the company said Wednesday. \n</p>\n<p>\n  The company's former auditor BF Borgers was banned from public-company work by the Securities and Exchange Commission in May for alleged fraud. \n</p>\n<p>\n  Shuttle said enrollment of patients in the Phase 2 clinical trial of ropidoxuridine for treatment of patients with glioblastoma has recently opened following the entry of agreements with two site locations to administer the trial. \n</p>\n<p>\n  During the regular trading session Wednesday, Shuttle shares rose 9% on volume of 10.8 million shares, compared with a 65-day average of 103,282. The stock was recently up 4% after hours, to $2.47. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 04, 2024 17:38 ET (21:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShuttle Pharmaceuticals Files Delayed Financial Statements, Reports Progress on Drug Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-05 05:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  Shuttle Pharmaceuticals Holdings filed delayed financial statements and reported progress in a clinical trial of cancer drug ropidoxuridine. \n\n\n  Shuttle filed its 10-Q for ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4097","symbol_name":"系统软件","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2465998537","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465998537","pubTimestamp":1725485880,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shuttle Pharmaceuticals Holdings filed delayed financial statements and reported progress in a clinical trial of cancer drug ropidoxuridine.Shuttle filed its 10-Q for the second quarter along with amended filings for the first quarter and 2023. As a result, it regained compliance with Nasdaq Listing Rule 5250, the company said Wednesday.The company's former auditor BF Borgers was banned from public-company work by the Securities and Exchange Commission in May for alleged fraud.Shuttle said enrollment of patients in the Phase 2 clinical trial of ropidoxuridine for treatment of patients with glioblastoma has recently opened following the entry of agreements with two site locations to administer the trial.During the regular trading session Wednesday, Shuttle shares rose 9% on volume of 10.8 million shares, compared with a 65-day average of 103,282. The stock was recently up 4% after hours, to $2.47.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4097":"系统软件","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4139":"生物科技","PRGS":"Progress Software Corporation","SHPH":"Shuttle Pharmaceuticals Inc"},"translate_title":"Shuttle Pharmaceuticals提交延迟的财务报表，报告药物研究进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1,"SHPH":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shuttle Pharmaceuticals Holdings filed delayed financial statements and reported progress in a clinical trial of cancer drug ropidoxuridine. \n\n\n  Shuttle filed its 10-Q for the second quarter along with amended filings for the first quarter and 2023. As a result, it regained compliance with Nasdaq Listing Rule 5250(c), the company said Wednesday. \n\n\n  The company's former auditor BF Borgers was banned from public-company work by the Securities and Exchange Commission in May for alleged fraud. \n\n\n  Shuttle said enrollment of patients in the Phase 2 clinical trial of ropidoxuridine for treatment of patients with glioblastoma has recently opened following the entry of agreements with two site locations to administer the trial. \n\n\n  During the regular trading session Wednesday, Shuttle shares rose 9% on volume of 10.8 million shares, compared with a 65-day average of 103,282. The stock was recently up 4% after hours, to $2.47. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 04, 2024 17:38 ET (21:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465998537"}